71 Participants Needed

Megestrol for Feeding Disorders in Children

(iKanEat Trial)

Recruiting at 7 trial locations
AM
KM
Overseen ByKelsey M Dean, RD, CCRP
Age: < 18
Sex: Any
Trial Phase: Phase 4
Sponsor: University of Kansas Medical Center
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

This is a multi-center, randomized, placebo-controlled, double-blind clinical trial. The primary focus of the study is the evaluation of the effectiveness of treatment with megestrol as part of a 24 week behavioral feeding protocol in transitioning from tube to oral feedings in a pediatric population. Approximately 60 pediatric subjects matching the criteria for eligibility will be enrolled in the study and randomized to receive either megestrol (n=30) or placebo (n=30).

Are You a Good Fit for This Trial?

The iKanEat trial is for children aged 9 months to 9 years with chronic oral food refusal who rely on tube feeding for over 80% of their daily calories. They must have the necessary oral and behavioral skills for eating, as assessed by a multidisciplinary team, and be medically stable to transition from tube to oral feeding.

Inclusion Criteria

Subjects must have a G or G/J tube.
Subjects must possess the oral motor skills necessary for eating. Subjects must possess behavioral skills necessary for mealtimes.
Subjects must have a ≥ 3 month history of feeding problems as identified by a diagnosis from a multidisciplinary feeding team, and must have permission from the physician on the team to ensure that they are medically stable enough to participate in a weaning study.
See 3 more

Exclusion Criteria

I am a parent with a condition that might make participating in the study hard.
Your parents do not speak English.
My child is currently receiving frequent behavioral feeding therapy.
See 1 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive either megestrol or placebo as part of a 24-week behavioral feeding protocol to transition from tube to oral feedings.

24 weeks
Regular visits as per protocol

Megestrol Tapering

Megestrol is dosed at full dose weeks 10-11, at 66% dose week 12, at 33% dose week 14, and fully tapered at the end of week 14.

4 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment, including assessments of child quality of life and parent stress.

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • iKanEat Behavioral Intervention
  • Megestrol Acetate
Trial Overview This study tests if megestrol combined with a behavioral feeding protocol helps kids switch from tube to mouth feeding. It's randomized: half get megestrol, half get placebo; neither doctors nor participants know who gets which. The treatment lasts for 24 weeks across multiple centers.
How Is the Trial Designed?
2Treatment groups
Experimental Treatment
Placebo Group
Group I: MegestrolExperimental Treatment2 Interventions
Group II: PlaceboPlacebo Group1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of Kansas Medical Center

Lead Sponsor

Trials
527
Recruited
181,000+
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security